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NeutralizationMerkel cell polyomavirus (MCV) has been implicated as a causative agent in Merkel cell carcinoma. Robust
polyclonal antibody responses against MCV have been documented in human subjects, but monoclonal
antibodies (mAbs) speciﬁc for the VP1 capsid protein have not yet been characterized. We generated
12 mAbs capable of binding recombinant MCV virus-like particles. The use of a short immunogenic priming
schedule was important for production of the mAbs. Ten of the 12 mAbs were highly effective for
immunoﬂuorescent staining of cells expressing capsid proteins. An overlapping set of 10 mAbs were able to
neutralize the infectivity of MCV-based reporter vectors, with 50% effective doses in the low picomolar range.
Three mAbs interfered with the binding of MCV virus-like particles to cells. This panel of anti-capsid
antibodies should provide a useful set of tools for the study of MCV.0 Rockville Pike, Bethesda, MD
Inc.Published by Elsevier Inc.Introduction
Merkel Cell Carcinoma (MCC) is a relatively rare cutaneous cancer
that occurs at a rate of approximately 1500 new cases per year in
the United States (Lemos and Nghiem, 2007). Several factors have
been linked to development of the disease, including advanced age
(over 65 years), sun exposure (Agelli and Clegg, 2003), and immuno-
suppression associated with HIV infection (Engels et al., 2002) or
organ transplant allografts (Penn and First, 1999). Merkel cell
polyomavirus (MCV) has recently been implicated as a causative
factor in most cases of MCC (Becker et al., 2008; Feng et al., 2008;
Garneski et al., 2008). Genetic material from this virus can commonly
be found in the skin of normal individuals (Foulongne et al., 2009;
Wieland et al., 2009), as well as in nasopharyngeal aspirates
(Bialasiewicz et al., 2009; Goh et al., 2009; Kantola et al., 2009),
saliva and other anatomical sites (Loyo et al., 2009). MCC tumors seem
to be non-productive for viral particles (Pastrana et al., 2009) and the
speciﬁc cell types in which MCV virions are produced in vivo have
not yet been determined.
MCV is a member of the family Polyomaviridae. Viruses in this
family have a non-enveloped icosahedral capsid that contains a
double stranded DNA viral genome. Polyomavirus virions are typically
composed of three structural proteins; VP1, VP2, and VP3. The majorcapsid protein, VP1, forms the surface of the virion,with 72pentameric
capsomers arranged on a T=7 icosahedral lattice. Roughly 72
molecules of the minor capsid proteins (VP2 or VP3) occupy the
interior of the capsid and are thought to be inaccessible to antibody
binding in the context of mature assembled virions (Norkin et al.,
2002). In contrast to other polyomaviruses, MCV appears to lack a VP3
protein (Pastrana et al., 2009). Recombinant polyomavirus VP1
proteins generally have the ability to self assemble into virus like
particles (VLPs) (Forstova et al., 1993), and MCV shares this property
(Pastrana et al., 2009; Tolstov et al., 2009). Recombinant VLPs are often
potently immunogenic and can serve as vaccines (Schiller and Lowy,
2001).
mAbs can be helpful in identifying key steps in the viral entry
pathway and understanding humoral immunity against the virus
(Klasse and Sattentau, 2002). In addition, mAbs directed against viral
structural proteins have been used in diagnosis of viral infections and
characterization of vaccine efﬁcacy (Chong et al., 2009; Fenwick et al.,
2006; Jahn et al., 1990; Karim and Pallesen, 2003; Morey et al., 1992;
Portolani et al., 2005; Smith et al., 2008). In this study we used MCV
VP1/VP2 VLPs as immunogens to generate mouse monoclonal anti-
bodies that should aid in the study of human MCV capsid protein
assembly and analysis of MCV's infectious entry pathway.
Results
VLPs from most virus species, including MCV (Pastrana et al.,
2009), have been shown to be very immunogenic. However, our
Table 1
Features of anti MCV VP1 monoclonal antibodies.
mAb Ig
isotype
Neutralizing EC50
(pM)
IF
reactivity
Denatured
reactivity
Protein L
binding
MV3 IgM 9.71 + − +
MV16 IgG2a Lowa ++ − −
MV18 IgM 2.09 + − −
MV23 IgG1 none ++ − −
MV26 IgM 0.68 +/− − +
MV27 IgM 1.81 + − +
MV32 IgM 0.72 + − +
MV42 IgM 0.76 ++ − −
MV49 IgM 2.29 NT + NT
MV57 IgM 3.70 bkg − +
MV62 IgM 1.10 + − +
MV167 IgM 5.11 ++ + +
Abbreviations in the table. NT: not tested, bkg: background.
a At the highest concentration tested, 50% neutralization was not reached and the
EC50 could not be calculated.
21Rapid Communicationexperience generating anti-MCV mAbs required three independent
attempts, revealing the sensitive nature of this seemingly well
established technique.
On the ﬁrst attempt, puriﬁed MCV VLPs were sent to a company
with a proven record for generating high quality mAbs. The company
utilized their standard prime/boost regimen and a standard SP2/0
myeloma fusion partner. Their schedule consisted of initial vaccina-
tion followed by a boost 28 days later and three more consecutive
boosts after 25 days. Test bleeds from the mice showed very high
titer MCV-speciﬁc antibody responses that were readily detectable in
VLP-based ELISA or in an MCV reporter vector-based neutralization
assay (Pastrana et al., 2009). An initial set of 24 hybridoma wells
were selected for their high reactivity to VLPs by ELISA. Of those
24 wells, supernatants from eight were able to neutralize the infec-
tivity of MCV reporter vectors with titers ranging from dilutions of
1:35 to 1:660 (data not shown). After expanding the cultures and/or
attempting to clone them by limiting dilution, all 24 cultures lost
MCV VLP reactivity. The company attributed the failure to “instability
of the clones”.
After this initial failure, we succeeded with an in-house generation
of stable hybridoma clones using a short immunogenic priming
schedule (Christensen et al., 1996) (discussed below). However, to
investigate the issue of whether the dosing schedule might have
been the primary factor in the company's failure to generate stable
hybridomas, we attempted to produce mAbs from a mouse primed
with MCV VLPs, then administered a single booster dose of VLPs
5 months later. In this attempt, lymphocytes were harvested from the
mouse 3 days after the booster dose. A dozen hybridomas that initially
secreted MCV-speciﬁc IgG antibodies were generated, but all 12
hybridomas became entirely non-reactive during the ﬁrst cloning
step. Another 12 MCV-speciﬁc IgM-secreting hybridoma wells
from the same fusion attempt were subjected to cloning by limiting
dilution. Four of the IgM hybridomas were ELISA-reactive after
cloning, but none of the four IgMs were capable of neutralizing the
infectivity of the MCV reporter vector (data not shown). The results
suggest that MCV VLP-speciﬁc hybridomas generated using standard
prime-boost regimens may not be generally capable of durable
antibody secretion.
The 12 successful mAbs described in this work were generated
using a protocol originally developed for production of mAbs
targeting human papillomavirus (HPV) VLPs (Christensen et al.,
1996). In this method, mice are euthanized for hybridoma production
2 weeks after initial immunization, without any intervening booster
dose. This dosing schedule appeared to be successful, with roughly
half of the initial 960 culture wells showing reactivity in VLP ELISA.
We initially screened the hybridomas from the unboosted mice
based on reactivity in a native VLP ELISA and reactivity in a denatured
VLP ELISA. A subset of the culture supernatants were screened for
the ability to neutralize an MCV-based reporter vector (data not
shown and Table 1). We selected a panel of 12 hybridoma clones for
detailed characterization. Of the 12 successful hybridoma clones
selected for full characterization, all were found to be reactive with
native VP1/VP2 VLPs. An additional screen showed that all 12 mAbs
were equally reactive with VP1-only VLPs and VP1/VP2 VLPs (data
not shown). This is consistent with the concept that little or no VP2 is
exposed on the native surface of the VLP.
Only 2 of the 12 mAbs were IgG; clone MV16 was IgG2a and clone
MV23 was IgG1. The other 10 clones were IgM isotype. Many appli-
cations require puriﬁed mAb, since crude culture supernatants
can have contaminants such as phenol red, albumin (and other
serum proteins), transferrin, etc. that interfere in certain assays. This
presented an obstacle since the most widely used methods for
puriﬁcation are protein A or protein G chromatography and neither
protein binds strongly to mouse IgMs. However, Protein L chroma-
tography is an alternative and equally straightforward puriﬁcation
method. Protein L binds through the immunoglobulin kappa lightchain. In mice this binding is restricted to the VkI light chain subtype
(Nilson et al., 1993). Since protein L does not bind bovine immu-
noglobulins, it is useful for purifying mAbs out of culture medium
containing serum. All 12 of the characterized mAbs were found to
have kappa isotype light chains andmost of the IgMmAbs in the panel
were found to bind protein L resin (Table 1).
Immunization with VLPs from HPVs and hepatitis B virus yields
mostly antibodies that bind conformational epitopes (Christensen
et al., 1994; Christensen and Kreider, 1990; Quan et al., 2007; Roden
et al., 1994). Our results suggest that this was also the case for the
MCV mAbs. Only MV49 and MV167, which are both IgM mAbs,
reacted in a denatured VLP ELISA (Table 1). These antibodies also
reacted to intact VLPs and were capable of neutralizing the MCV
reporter vector, which implies that they might recognize linear
epitopes on the surface of the intact viral particles. We also assessed
the ability of antibodies to recognize linear epitopes by immuno-
blotting of proteins from denaturing SDS-PAGE gels. Although
polyclonal serum from VLP-immunized mice was highly effective for
speciﬁc detection of VP1 in Western blots, none of the 12 mAbs were
able to detect VP1 by immunoblotting (data not shown). A possible
explanation for the apparent discrepancy between the denaturing
ELISA results for MV49 and MV167 and their results in Western might
be that, in the ELISA format, the VP1 protein undergoes partial
renaturation during binding to the ELISA well.
To test whether the MCV mAbs would be useful for detecting VP1
expressed intracellularly, we transfected HeLa cells with plasmids
encoding either MCV VP1/VP2, or the L1 and L2 capsid proteins of
HPV16 as a negative control (Fig. 1 and data not shown). One of the
mAbs, MV57, showed signiﬁcant cytoplasmic background in both the
HPV16 and MCV transfected cells, making it unsuitable for immuno-
ﬂuorescent analysis (data not shown). The rest of the mAbs (except
for MV49, which was not tested) showed nuclear staining in the
MCV VP1/2 transfected cells, but not in the HPV transfected cells.
The strength of the signal varied with each antibody, with the two
IgG mAbs (MV16 and MV23) giving the strongest signal, followed
by MV42 and MV167. The greater strength of the signal for MV16
and MV23 could theoretically reﬂect better secondary antibody
detection of IgG isotype antibodies, as opposed to more efﬁcient
primary antibody binding.
We also tested the ability of the mAbs to detect capsid proteins in
sections of formalin-ﬁxed parafﬁn embedded VP1-transfected cells.
Although polyclonal mouse and rabbit sera were both able to detect
MCV VP1/2 in this context, none of the mAbs were reactive (Pastrana
et al., 2009, and data not shown). Several traditional antigen retrieval
techniques were attempted, including varying the type (microwave,
autoclave, water bath) and timing of the heat source, changing the
pH of the retrieval buffer (neutral, acidic, basic) or utilizing trypsin
Fig. 1. Monoclonal antibodies are able to recognize VP1/VP2 in cells. HeLa cells were
transfected with plasmids that express either MCV VP1/VP2 or HPV16 L1/L2 as a
negative control. Cells were seeded onto glass coverslips and stained. Three repre-
sentative mAbs are shown.
Fig. 2. Monoclonal antibodies block binding of MCV VLPs to cells. A549 cells were
treated with dye conjugated MCV VLPs in the presence of different concentrations of
mAbs. Antibody dose is expressed as the molar ratio of IgM molecules to assembled
capsids.
22 Rapid Communicationdigestion. None of the alternative processing methods allowed for
recognition of VP1 in the parafﬁn section samples.
For HPVs, it is thought that most antibodies that are capable of
recognizing native virus-like particles are also capable of neutralizing
the infectivity of the authentic virus. Although it is not yet possible to
generate native MCV virions, we have previously reported a system
for measuring antibody-mediated suppression of the infectivity
of MCV-based reporter vectors (Pastrana et al., 2009; Tolstov et al.,
2009). The vector system serves as a useful proxy measure for the
potential effect of mAbs on the infectivity of MCV. We used the MCV
reporter vector system to determine the endpoint neutralizing
titers of the mAbs. Surprisingly, both of the IgG antibodies had either
very low or undetectable neutralizing activity against the MCV vector
(Table 1). In contrast, all the IgM clones were able to neutralize the
infectivity of theMCV reporter vector. Quantitation of the IgM content
of the supernatants indicated that calculated 50% effective concen-
trations (EC50) of the mAbs ranged from 0.7 to 9.7 picomolar (pM)
(Table 1).
To investigate the mechanism by which the mAbs neutralize
infectivity of the MCV reporter vector, an arbitrary subset of three
neutralizing mAbs were chosen for puriﬁcation and subsequent
analysis of their ability to block the binding of MCV VLPs to cells.
Alexa Fluor conjugated VLPs were brieﬂy preincubated with protein
L-puriﬁed mAbs. The resulting virion-antibody complexes were
then mixed with suspended A549 cells, incubated 1 h at 37 °C, then
analyzed by ﬂow cytometry (Fig. 2). Each of the three mAbs exam-
ined effectively blocked the binding of MCV VLPs to cells.
Discussion
The recent discovery and association of MCV with MCC, and the
widespread distribution of the virus among the human populationcalls for close examination of natural MCV infection. In order to
address these questions it is critical to develop reagents, such as
mAbs targeting the viral capsid. In this study we present a panel of
mAbs that are capable of neutralizing MCV reporter vectors with
EC50s in the low picomolar to high femtomolar range and are useful
for speciﬁc immunoﬂuorescent detection of VP1 capsid protein
expression in cultured cells. The primary utility of the mAbs
presented in this work will likely be for dissection of the infectious
entry pathway MCV uses to infect cells and for the analysis of VP1
expression in cultured cells.
The binding of biotin to avidin is one of the strongest non-covalent
interactions known, with an afﬁnity constant of roughly 1 fM (Green,
1975). In contrast, it is uncommon for mAbs to be capable of neu-
tralizing viruses at doses in the femtomolar range. For example, one
of the highest-afﬁnity mAbs capable of neutralizing HPV type 16,
mAb H16-V5, displays an EC50 value of about 2 pM in vector-based
neutralization assays (Day et al., 2007). Likewise, several neutralizing
mAbs speciﬁc for human cytomegalovirus (Macagno et al., 2010) are
effective in the 5–200 pM range. All 10 of our IgM mAbs displayed
neutralizing EC50s in the low picomolar to high femtomolar range and
are thus, as a group, unusually potent neutralizing mAbs. The high
valency of the IgM mAbs together with the highly repetitive nature of
the MCV capsid surface could account for the apparently high avidity
of our mAbs (Racine and Winslow, 2009).
Virus-neutralizing mAbs can block infection either by interfering
with attachment of the virus to the cell or by preventing post-
attachment events that lead to successful infection. All three of the
MCV vector-neutralizing IgM mAbs we tested were capable of
blocking the association of MCV VLPs with cells, suggesting that this
is their primary mechanism of neutralizing the infectivity of the MCV
reporter vector. Given the assumption that all of the VP1 in the MCV
VLP stock is assembled into full-size capsids, 50% inhibition of VLP
binding to cells occurred at an antibody to capsid molar ratio of about
18. The ability of so few IgM molecules to interfere with binding is
consistent with the large steric bulk of the pentavalent ∼900 kDa IgM
structure. Recent work suggests that IgM molecules are capable of
binding in a planar conﬁguration parallel to the surface of the capsid
(Czajkowsky and Shao, 2009), thus maximizing the amount of
blocked surface area.
Polyclonal antibody responses against MCV VP1 tend to be very
robust in VLP-immunized mice and rabbits, as well as in a minority
of naturally MCV-infected humans (Pastrana et al., 2009). Given
the apparent strength of humoral responses to the MCV capsid, we
expected that generation of mAbs using standard antigen dosing
schedules would be technically straightforward. However, two
attempts at producing VLP-speciﬁc mAbs were entirely unsuccessful,
yielding hybridomas that rapidly lost the ability to secrete capsid-
speciﬁc mAbs. Through a personal communication (Patricia Day, NCI,
23Rapid CommunicationNIH, Bethesda, MD) we learned that use of a traditional prime/boost
schedule to generate mAbs against HPV16 VLPs likewise yielded only
unstable IgG hybridomas and non-neutralizing IgMs, whereas success
was obtained for the same stock of HPV particles using the shorter
2 week single-immunization schedule. Similarly, a recent paper by
Senger et al. (2009) showed that out of 28 mAbs raised against HPV27
using a standard prime-boost dosing schedule, only one mAb was IgG
and the rest were IgMs, only one of which was neutralizing. A possible
explanation for the results might be that repetitively arrayed VLP
immunogens provide an inappropriately strong stimulus to B cells
when administered as a boost 3 days prior to lymphocyte harvest. It
has previously been suggested that viral capsid antigens often fail to
elicit afﬁnity maturation, suggesting that B cells responding to
repetitively arrayed antigens may be functionally different from B
cells responding to non-arrayed antigens (Roost et al., 1995) and
might need a different protocol to obtain stable hybridomas. The
use of a single priming dose 2 weeks prior to lymphocyte harvest
(Christensen et al., 1996) appears to present a tractable approach to
circumventing the hybridoma instability problem. Although the
short dosing schedule yielded mostly IgM isotype mAbs, an initial
ELISA screen using an IgG-speciﬁc secondary could readily be used to
select IgG isotype mAbs.
The mAbs that we generated had very low background staining in
several cell types (293TT, A549, CHOs; data not shown), which is an
essential requirement for in vitro staining work. As the ﬁeld of MCV
research advances and begins to include in vitro and in vivo studies,
the antibodies described in this manuscript should contribute to these
efforts.
Materials and methods
Mice and immunization
Eight week old female BALB/cAnNCr were purchased from Charles
River Laboratories. Mice were housed and handled under speciﬁc
pathogen-free conditions in the animal care facilities at National
Cancer Institute in accordance with institutional guidelines. Experi-
mental procedures were approved by the National Cancer Institute
Animal Care and Use Committee.
Generation of monoclonal antibodies
Merkel Cell Polyomavirus VP1/VP2 virus like particles (VLPs) were
produced as previously described (Tolstov et al., 2009). Three BALB/c
micewere vaccinated subcutaneously with 10 μg of VLPs emulsiﬁed in
50 μl of complete Freund's adjuvant (CFA, Sigma). For the successful
single immunization regimen, two mice were euthanized 2 weeks
after immunization. The third primed mouse received a booster
immunization 150 days after the initial dose with 100 μg of VLPs in
saline. The boosted mouse was euthanized 3 days after boost. Spleen
and draining lymph node single cell suspensions were obtained
after enzymatic digestion with collagenase A and DNAse 1 (Roche).
Lymphoid cells (50 million) were fused to 30 million SP2/mIL6 cells
(Harris et al., 1992) (ATCC) in 37 °C RPMI supplemented dropwise
with PEG-1500 solution (Roche). All subsequent culture steps were
performed using RPMI medium supplemented with Hybridoma
Fusion and Cloning Supplement (HFCS, Roche), 10% fetal calf serum,
1% Glutamax-I (Invitrogen), 24 μM 2-mercaptoethanol, and Primocin
(Invivogen). The fused cells were divided into ten 96-well plates.
Selected ELISA-positive primary hybridoma wells were expanded for
several days then subjected to two rounds of cloning by limiting
dilution. The resulting mAbs were isotyped using Roche's IsoStrip
mouse monoclonal antibody isotyping kit. Ambiguous isotyping
results were re-analyzed using AbD Serotec's mouse isotyping test
strips.ELISAs
Direct enzyme-linked immunosorbent assays (ELISA) were per-
formed using Immulon HB2 plates (Thermo) coated overnight at
50 ng of VLPs per well in 100 μl PBS. The wells were blocked with PBS
with 1% nonfat dry milk (LabScientiﬁc). The hybridoma-conditioned
supernatants were diluted 1:2 in block, transferred into the ELISA
plates and allowed to shake for 1 to 2 h at room temperature. The
plates were washed with PBS and the secondary antibody was goat
anti-mouse IgG (H+L) conjugated to horseradish peroxidase (HRP)
(BioRad) diluted 1:5000 in block. To screen speciﬁcally for IgG isotype
antibodies, a highly cross-adsorbed IgG-speciﬁc goat anti-mouse HRP
conjugate (Southern Biotech) was used at 1:5000. ABTS substrate
(Roche) was used as an HRP substrate and absorbance was measured
at 405 nm with a reference read at 490 nm.
For detection of denatured VLPs, 100 μl of 0.5 mg/ml VLP stock
was adjusted to 2% SDS, 50 mMDTT, 25 mM EDTA and 50 mM Tris pH
8.5. The sample was heated at 65 °C for 10 min then diluted in PBS to a
ﬁnal concentration of 50 ng/well in 100 μl.
Neutralization assay
Neutralization of MCV reporter vectors by monoclonal antibodies
was performed as previously described (Pastrana et al., 2009), except
that a lower dose of MCV reporter vector (5 fM with respect to VP1
monomer) was used for the current work. Brieﬂy, MCV-based Gaussia
luciferase reporter vector was mixed in a 96-well plate format with
serial dilutions of hybridoma-conditioned medium for 1 h at 4 °C. The
vector plus antibody mixture was added to 30,000 293TT cells (Buck
et al., 2004). The serum used for hybridoma cultures and for 293TT
cell culture was heat-inactivated at 56 °C for 30 min to inhibit com-
plement activity. Seventy-two hours after addition of the vector/
antibodymixtures, 25 μl of 293TT culture supernatant was transferred
to an Optiplate-96 well plate (Perkin Elmer). A BMG Labtech Polarstar
Optima luminometer was used to inject 50 μl of Gaussia Luciferase
Assay Kit substrate and light emitted was measured at a gain of 2500.
The 50% effective neutralizing concentration (EC50) for each mAb
was calculated using Prism software (Graphpad).
Quantitation and puriﬁcation of mAbs in conditioned supernatants
The concentration of IgM in the conditioned supernatants used for
neutralization assays was performed using a capture ELISA strategy.
Plates were coated with an unconjugated goat anti-mouse kappa light
chain preparation (Southern Biotech). The coated wells were used to
capture IgM from serial dilutions of hybridoma supernatants or serial
dilutions of a standard IgMmAb (Seikagaku) of known concentration.
Captured IgM was detected using an Alexa Fluor 488 conjugated goat
anti-mouse IgM secondary (Invitrogen). Fluorescence was detected
using a BMG Polarstar device. The quantitation was conﬁrmed in a
separate experiment using goat anti-mouse IgG (H+L)-HRP second-
ary (BioRad). Puriﬁcation of the mAbs out of conditioned super-
natant was performed using Pierce's Nab Protein L resin according to
manufacturer's instructions. Concentration and purity of the mAbs
was determined by absorbance at 280 nm wavelength and by SDS-
PAGE analysis.
Immunoﬂuorescence staining
Five million HeLa cells (ATCC) were transfected with 38 μg of
either plasmid pwM2m or p16L1L2 (Buck et al., 2008) using
Lipofectamine 2000 (Invitrogen) as recommended by the manufac-
turer. Maps of plasmids used in this work are available from our
laboratory website bhttp://home.ccr.cancer.gov/LCO/N. After 24 h
cells were trypsinized and rinsed in PBS. One third of the cells were
plated onto coverslips, the remaining two thirds were sent for parafﬁn
24 Rapid Communicationembedding (see below). For the coverslips, the cells were allowed to
attach for an additional 24 h, rinsed in PBS and ﬁxed for 10 min at
room temperature with 10% neutral buffered formalin (Fisher). Fixed
coverslips were incubated with PBS+200 mM glycine for 10 min.
Hybridoma conditioned supernatants were diluted 1:10 in PBS+0.1%
Brij-58 (PBS/Brij) at 37 °C for 2 h. Goat anti-mouse or anti-rabbit
Alexa Fluor 488 conjugated antibodies (Invitrogen) were diluted to
1 μg/ml and incubated for 1 h at room temperature.
For parafﬁn embedding, transfected HeLa cells were ﬁxed at room
temperature for 20 min, rinsed thrice with PBS/200 mM glycine and
sent for parafﬁn processing and sectioning (Histoserve). Sections
were baked onto glass slides at 60 °C for 1 h, and deparafﬁnized as
previously described (Pastrana et al., 2009). Antigen retrieval was
performed using pH 6 citrate buffer, pH 9 Tris/EDTA buffer (both from
Dako), or 20 mM Tris, 25 mMNaCl pH 7.5. The heating sources were a
95 °C water bath for 30 min, microwaving for 5 min at a low boil (30%
power), and 10 min of autoclaving at 120 °C with a liquid cycle.
All heating retrieval methods were followed by 20 min cool down at
room temperature. Slides were then rinsed three times in PBS and
stained as described above for the coverslips. Prolong Gold Antifade
with Dapi (Invitrogen) was used as a mounting medium and confocal
microscopy was performed using a Zeiss NLO 510 instrument.
VLP-cell binding assay
VLPs were labeled using Alexa Fluor 488 labeling kit (Invitrogen)
according to manufacturer's instructions. Brieﬂy, MCV VLPs were
produced in 293TT cells transfected with pwM2m. The cells were
lysed and incubated at 37 °C to promote capsid maturation. The lysate
was adjusted to 800 mM NaCl then clariﬁed by centrifugation 10 min
at 5000×g, then the clariﬁed lysate was diluted 1:3 with water, then
1/10th of a volume of 1 M sodium bicarbonate was added. Half a
milliliter of the mixture was transferred to an Alexa Fluor tube
provided with the kit and stirred at room temperature for 1 h. The
mixture was then returned to neutral pH by the addition of 20 μl of
1 M sodium phosphate adjusted to pH 6.5, followed by Optiprep
puriﬁcation, as above. VLP concentration in the puriﬁed stock was
determined by comparing VP1 to bovine serum albumin standards in
Coomassie-stained SDS-PAGE gels. A detailed protocol for the labeling
procedure is available at our laboratory website bhttp://home.ccr.
cancer.gov/LCON.
The binding assay was performed by ﬁrst dislodging A549 cells
using CellStripper reagent (Cellgro Mediatech). One hundred thou-
sand cells were washed into Dulbecco's PBS with calcium and
magnesium (DPBS, Invitrogen) supplemented with 1% fetal bovine
serum, 10 mM HEPES (pH 8) and antibiotics, then treated with
0.75 ng of Alexa Fluor conjugated VLPs pre-mixed for 10 min with
500, 100, or 20 ng of puriﬁedmAbsMV3, MV32 andMV62. Molar ratio
calculations were performed assuming a 900 kDa mass for IgM and
assuming that all VP1 was in the form of full size capsids (mass
16,740 kDa). The cell/VLP/antibody mixture was incubated for 1 h at
37 °C. The cells were then washed 3× and their ﬂuorescence was
measured by ﬂow cytometry using a FACSCanto II (BD Biosciences).
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